C12N 2710/10321
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2710/10321 (Viruses as such) appears on 163 US grants and 240 published applications in this corpus.
Search patents in C12N- Granted patents
- 163
- Published applications
- 240
- Assignees
- 108
- Inventors
- 336
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 5 | 0 |
| 2000 | 4 | 0 |
| 2001 | 7 | 1 |
| 2002 | 2 | 4 |
| 2003 | 2 | 6 |
| 2004 | 4 | 4 |
| 2005 | 2 | 10 |
| 2006 | 1 | 7 |
| 2007 | 3 | 7 |
| 2008 | 1 | 3 |
| 2009 | 3 | 8 |
| 2010 | 2 | 8 |
| 2011 | 2 | 9 |
| 2012 | 8 | 7 |
| 2013 | 5 | 10 |
| 2014 | 6 | 8 |
| 2015 | 10 | 11 |
| 2016 | 6 | 13 |
| 2017 | 7 | 17 |
| 2018 | 12 | 10 |
| 2019 | 9 | 14 |
| 2020 | 11 | 14 |
| 2021 | 7 | 16 |
| 2022 | 15 | 14 |
| 2023 | 9 | 14 |
| 2024 | 4 | 10 |
| 2025 | 11 | 9 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Oncolytic non-human adenoviruses and uses thereof30 Jun 2026US 12,668,612 B2Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Modified oncolytic adenoviruses12 May 2026US 12,622,935 B2Valo Therapeutics Oy
- Desmoglein 2 (DSG2) binding proteins and uses therefor11 Nov 2025US 12,466,859 B2University of Washington through its Center for Commercialization
- Single plasmid vector system for packaging recombinant human adenovirus type 4 and application thereof4 Nov 2025US 12,460,227 B2Academy of Military Medical Science, PLA
- Methods and compositions for producing an adenovirus vector for use with multiple vaccinations29 Jul 2025US 12,370,250 B2Etubics Corporation
- Adenovirus vector circular rna expression system8 Oct 2026US 2026/0306666 A1
- Oncolytic non-human adenoviruses and uses thereof17 Sep 2026US 2026/0274898 A1Academisch Ziekenhuis Leiden (H.O.D.N. Lumc)
- Recombinant oncolytic adenovirus for cancer therapy20 Aug 2026US 2026/0240928 A1The Johns Hopkins University
- Oncolytic adenovirus compositions with enhanced replication properties18 Jun 2026US 2026/0167940 A1The Salk Institute for Biological Studies
- A replicative oncolytic adenovirous capable of inhibiting tumor progression and prolonging survival time in tumor-bearing individuals and use thereof19 Feb 2026US 2026/0049337 A1
Most cited
By later US patents
- Packaging systems for human recombinant adenovirus to be used in gene therapy267US 5,994,128 AIntrogene B.V. · 1999
- Hybrid adenovirus-AAV virus and methods of use thereof198US 6,251,677 B1The Trustees of the University of Pennsylvania · 2001
- Packaging systems for human recombinant adenovirus to be used in gene therapy178US 6,033,908 AIntrogene B.V. · 2000
- Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use102US 7,247,472 B2The Trustees of the University of Pennsylavania · 2007
- Cytopathic viruses for therapy and prophylaxis of neoplasia87US 5,846,945 AOnyx Pharmaceuticals, Inc. · 1998